Randomized controlled trials: a solid platform for observational research.

about

Randomized controlled trials: a solid platform for observational research.

Item

http://www.wikidata.org/entity/Q53786641

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Randomized controlled trials: a solid platform for observational research.

@en

Randomized controlled trials: a solid platform for observational research.

@nl

type

Item

label

Randomized controlled trials: a solid platform for observational research.

@en

Randomized controlled trials: a solid platform for observational research.

@nl

prefLabel

Randomized controlled trials: a solid platform for observational research.

@en

Randomized controlled trials: a solid platform for observational research.

@nl

P1476

Randomized controlled trials: a solid platform for observational research

@en

P2093

Erik R Swenson

http://www.w3.org/2001/XMLSchema#string

P2860

Future perspectives in pulmonary arterial hypertension

SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.

Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses

Are hemodynamics surrogate end points in pulmonary arterial hypertension?

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):

An official American Thoracic Society Statement: pulmonary hypertension phenotypes

Surrogate and combined end points in pulmonary arterial hypertension.

How to use a subgroup analysis: users' guide to the medical literature.

Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency.

Use and misuse of the receiver operating characteristic curve in risk prediction.

P304

1156-1158

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHX123

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Peter Leary

P577

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28379468

http://www.w3.org/2001/XMLSchema#string